This page contains a Flash digital edition of a book.
Acute Kidney Injury


specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury, Ann Intern Med, 2008;148:810–9.


67.


Boldt J, Brosch C, Ducke M, et al., Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin, Crit Care Med, 2007;35:2740–6.


68.


Boldt J, Brosch Ch, Rohm K, et al., Comparison of the effects of gelatin and a modern hydroxyethylstarch solution on renal function and inflammatory response in elderly cardiac surgery patients, Br J Anaesth, 2008;100:457–64.


69.


Boldt J, Suttner S, Brosch C, et al., Cardiopulmonary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy, Anesth Analg, 2009;109(6):1752–62.


70.


Haase M, Fielitz-Haase A, Bellomo R, et al., Sodium bicarbonate to prevent acute kidney injury after cardiac surgery: a pilot double-blind, randomized controlled trial, Crit Care Med, 2009;37(1):39–47.


71.


Capuano F, Goracci M, Luciani R, et al., Neutrophil gelatinase-associated lipocalin levels after use of mini- cardiopulmonary bypass system, Interact Cardiovasc Thorac Surg, 2009;9(5):797–801.


72.


Dent CL, Ma Q, Dastrala S, et al., Plasma NGAL predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study, Crit Care, 2007;11:R127.


73. 74. 75.


Bennett M, Dent CL, Ma Q, et al., Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study, Clin J Am Soc Nephrol, 2008;3,665–73.


Trachtman H, Christen E, Cnaan A, et al., Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury, Pediatr Nephrol, 2006;21:989–94.


Kumpers P, Hafer C, Lukasz A, et al., Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury, Crit Care, 2010;14:R9.


76.


de Geus HR, Betjes MG, Bakker J, Neutrophil gelatinase- associated lipocalin clearance during veno-venous continuous renal replacement therapy in critically ill patients, Intensive Care Med, 2010;36(12):2156–7.


77. 78. 79. 80.


Mori K, Nakao K, Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage, Kidney Int, 2007;71(10):967–70.


Bobek I, Gong D, De Cal M, et al., Removal of neutrophil gelatinase-associated lipocalin by extracorporeal therapies, Hemodial Int, 2010;14(3):302–7.


Devarajan P, Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury, Biomark Med, 2010;4(2):265–80.


Grenier FC, Ali S, Syed H, et al., Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability, Clin Biochem, 2010;43(6):615–20.


81. 82. 83. 84. 85. 86.


Haase-Fielitz A, Haase M, Bellomo R, Instability of urinary NGAL during long-term storage, Am J Kidney Dis, 2009;53:564–5.


Mitsnefes M, Kathman T, Mishra J, et al., Serum NGAL as a marker of renal function in children with chronic kidney disease, Pediatr Nephrol, 2007;22:101–8.


Devarajan P, The promise of biomarkers for personalized renal cancer care, Kidney Int, 2010;77(9):755–7.


Goldstein SL, Devarajan P, Acute kidney injury in childhood: should we be worried about progression to CKD?, Pediatr Nephrol, 2010 (Epub ahead of print),


Devarajan P, The use of targeted biomarkers for chronic kidney disease, Adv Chronic Kidney Dis, 2010;17(6):469–79.


Bolignano D, Lacquaniti A, Coppolino G, et al., Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease,


97. Kidney Blood Press Res, 2008;31:255–8. 87.


Bolignano D, Coppolino G, Campo S, et al., Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients, Nephrol Dial Transplant, 2008;23:414–6.


88. 89.


Bolignano D, Lacquaniti A, Coppolino G, et al., Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease, Clin J Am Soc Nephrol, 2009;4(2):337–44.


Meijer E, Boertien WE, Nauta FL, et al., Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross- sectional analysis, Am J Kidney Dis, 2010;56(56):883–95.


90.


Ding H, He Y, Li K, et al., Urinary neutrophil gelatinase- associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy, Clin Immunol, 2007;123:227–34.


91. 92.


Brunner HI, Mueller M, Rutherford C, et al., Urinary NGAL as a biomarker of nephritis in childhood-onset SLE, Arthritis Rheum, 2006;54:2577–84.


Suzuki M, Wiers KM, Klein-Gitelman MS, et al., Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis, Pediatr Nephrol, 2008;23:403–12.


93.


Hinze CH, Suzuki M, Klein-Gitelman M, et al., Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity, Arthritis Rheum, 2009;60(9):2772–81.


94. 95. 96.


Yilmaz A, Sevketoglu E, Gedikbasi A, et al., Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin, Pediatr Nephrol, 2009;24(12):2387–92.


Cai L, Rubin J, Han W, Venge P, Xu S, The origin of multiple molecular forms in urine of HNL/NGAL, Clin J Am Soc Nephrol, 2010;5(12):2229–35.


Ichimura T, Bonventre JC, Bailly V, et al., Kidney Injury Molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury, J Biol Chem, 1998;273:4135–42.


Vaidya VS, Ramirez V, Ichimura T, et al., Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury, Am J Physiol Renal Physiol, 2006;290:F517–29.


98.


Liangos O, Periyanayagam MC, Vaidya VS, et al., Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure, J Am Soc Nephrol, 2007;18(3):904–12.


99.


Han WK, Waikar SS, Johnson A, et al., Urinary biomarkers in the early diagnosis of acute kidney injury, Kidney Int, 2008;73(7):863–9.


100. Liangos O, Tighiouart H, Perianayagam MC, et al., Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass, Biomarkers, 2009;14(6):423–31.


101. Vaidya VS, Ozer JS, Dieterle F, et al., Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies, Nat Biotechnol, 2010;28(5):478–85.


102. Vaidya VS, Ford GM, Waikar SS, et al., A rapid urine test for early detection of kidney injury, Kidney Int, 2009;76(1):108– 14.


103. van Timmeren MM, van den Heuvel MC, Bailly V, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease, J Pathol, 2007;212(2):209–17.


104. van Timmeren MM, Vaidya VS, van Ree RM, et al., High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients, Transplantation, 2007;84(12):1625–30.


105. Waanders F, Vaidya VS, van Goor H, et al., Effect of renin- angiotensin-aldosterone system inhibition, dietary sodium


restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial, Am J Kidney Dis, 2009;53(1):16–25.


106. Noiri E, Doi K, Negishi K, et al., Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury, Am J Physiol Renal Physiol, 2009;296(4):F669–79.


107. Yamamoto T, Noiri E, Ono Y, et al., Renal L-type fatty acid—binding protein in acute ischemic injury, J Am Soc Nephrol, 2007;18(11):2894–902.


108. Negishi K, Noiri E, Doi K, et al., Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury, Am J Pathol, 2009;174(4):1154–9.


109. Portilla D, Dent C, Sugaya T, et al., Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery, Kidney Int, 2008;73(4):465–72.


110. Ferguson MA, Vaidya VS, Waikar SS, et al., Urinary liver- type fatty acid-binding protein predicts adverse outcomes in acute kidney injury, Kidney Int, 2010;77(8):708–14.


111. Doi K, Noiri E, Maeda-Mamiya R, et al., Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury, Crit Care Med, 2010;38(10):2037–42.


112. Kamijo A, Sugaya T, Hikawa A, et al., Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease, Mol Cell Biochem, 2006;284(1–2):175–82.


113. Nakamura T, Sugaya T, Kawagoe Y, et al., Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy, Diabetes Care, 2005;28(11):2728–32.


114. Ishimitsu T, Ohta S, Saito M, et al., Urinary excretion of liver fatty acid-binding protein in health-check participants, Clin Exp Nephrol, 2005;9(1):34–9.


115. Melnikov VY, Ecder T, Fantuzzi G, et al., Impaired IL-18 processing protects caspase-1 deficient mice from ischemic acute renal failure, J Clin Invest, 2001;107:1145–52.


116. Parikh CR, Jani A, Melnikov VY, et al., Urinary interleukin-18 is a marker of human acute tubular necrosis, Am J Kidney Dis, 2004;43:405–14.


117. Parikh CR, Abraham E, Ancukiewicz M, et al., Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit, J Am Soc Nephrol, 2005;16:3046–52.


118. Washburn KK, Zappitelli M, Arikan AA, et al., Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children, Nephrol Dial Transplant, 2008;23(2):566–72.


119. Leslie JA, Meldrum KK, The role of interleukin-18 in renal injury, J Surg Res, 2008;145(1):170–5.


120. Shapiro NI, Trzeciak S, Hollander JE, et al., A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis, Crit Care Med, 2009;37(1):96–104.


121. Shapiro NI, Trzeciak S, Hollander JE, et al., The diagnostic accuracy of plasma neutrophil gelatinase-associated lipocalin in the prediction of acute kidney injury in emergency department patients with suspected sepsis, Ann Emerg Med, 2010;56(1):52–59.e1.


122. Heise D, Rentsch K, Braeuer A, Friedrich M, Quintel M, Comparison of urinary neutrophil glucosaminidase- associated lipocalin, cystatin C, and alpha(1)-microglobulin for early detection of acute renal injury after cardiac surgery, Eur J Cardiothorac Surg, 2010 (Epub ahead of print).


123. Koyner JL, Vaidya VS, Bennett MR, et al., Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury, Clin J Am Soc Nephrol, 2010;5(12): 2154–65.


124. Devarajan P, Krawczeski CD, Nguyen MT, et al., Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children, Am J Kidney Dis, 2010;56(4):632–42.


44


US NEPHROLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100